【醫(yī)學(xué)課件】lipid研究ppt課件-資料下載頁
2025-10-10 06:49本頁面
【正文】 L 25 (1237) 133230 mg/dL 24 (937) 230 mg/dL 24 (241) Reduction in Risk (95% CI) N Engl J Med 1998。339:134957 LIPID Risk Reduction in Prespecified Subgroups ? With respect to the bined endpoint of death from CHD and nonfatal MI: – There was no evidence of significant heterogeneity (P ) of the treatment effect in any of the subgroups defined by sex, age, initial lipid levels, and the presence or absence of other risk factors, (., hypertension, smoking and diabetes) – The reduction in risk with pravastatin treatment in each subgroup was consistent with the overall 24% reduction in risk for the entire cohort. N Engl J Med 1998。339:134957 LIPID Summary of Results ? Over a period of years, in 48 patients for every 1000 randomly assigned to treatment with pravastatin the following events were avoided (with allowance for multiple events in each patient) : – 30 deaths – 28 nonfatal MIs – 9 nonfatal strokes – 23 episodes of CABG – 20 episodes of PTCA – 82 hospital admissions for unstable angina N Engl J Med 1998。339:134957 LIPID Conclusion ? Pravastatin therapy reduced mortality from CHD and overall mortality, as pared with placebo, as well as the incidence of all prespecified cardiovascular events in patients with a history of MI or unstable angina who had a broad range of initial cholesterol levels. N Engl J Med 1998。339:13495
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1